HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Thrombolytic therapy is effective in paroxysmal nocturnal hemoglobinuria: a series of nine patients and a review of the literature.

AbstractBACKGROUND:
Thrombosis is the major risk factor for death in patients with paroxysmal nocturnal hemoglobinuria. Previous case reports indicate that venous thrombosis in patients with paroxysmal nocturnal hemoglobinuria is amenable to thrombolysis.
DESIGN AND METHODS:
We reviewed the outcome of thrombolytic therapy for patients with paroxysmal nocturnal hemoglobinuria who had thromboses refractory to anticoagulation at our institutions.
RESULTS:
In this study of 41 patients who had at least one thrombotic event, we confirmed a very high incidence of recurrence despite anticoagulation. Nine patients with thrombosis were regarded as eligible for administration of intravenous tissue plasminogen activator, which was effective in reversing thrombi in all of 15 occasions in which it was given. Serious hemorrhagic complications developed in three cases. At last follow-up visit, of the nine patients treated, three had died, and six were in very good to excellent condition in terms of clinical outcome and radiological findings. The only patient in whom thrombolysis may have contributed to a fatal outcome also had complications of "heparin induced thrombocytopenia with thrombosis", which we diagnosed in three additional patients. In our review of the literature, nine out of 15 patients treated with thrombolysis have had a good outcome.
CONCLUSIONS:
Although it is associated with a significant but manageable risk of bleeding, systemic thrombolysis is a highly effective treatment for reversing venous thromboses in patients with paroxysmal nocturnal hemoglobinuria.
AuthorsDavid J Araten, Rosario Notaro, Howard T Thaler, Nancy Kernan, Farid Boulad, Hugo Castro-Malaspina, Trudy Small, Andromachi Scaradavou, Heather Magnan, Susan Prockop, Sara Chaffee, Jason Gonsky, Raymond Thertulien, Roberto Tarquini, Lucio Luzzatto
JournalHaematologica (Haematologica) Vol. 97 Issue 3 Pg. 344-52 (Mar 2012) ISSN: 1592-8721 [Electronic] Italy
PMID22133780 (Publication Type: Case Reports, Journal Article, Research Support, U.S. Gov't, Non-P.H.S., Review)
Chemical References
  • Anticoagulants
  • Fibrinolytic Agents
  • Tissue Plasminogen Activator
Topics
  • Adolescent
  • Adult
  • Aged
  • Anticoagulants (therapeutic use)
  • Fatal Outcome
  • Female
  • Fibrinolytic Agents (administration & dosage, therapeutic use)
  • Hemoglobinuria, Paroxysmal (complications, diagnosis, drug therapy)
  • Humans
  • Male
  • Middle Aged
  • Pregnancy
  • Recurrence
  • Risk Factors
  • Thrombolytic Therapy
  • Tissue Plasminogen Activator (administration & dosage, therapeutic use)
  • Treatment Outcome
  • Venous Thrombosis (diagnosis, drug therapy, etiology)
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: